Geographic Atrophy

• FDA approval · 2026-02-27
  FDA Approved: IZERVAY — Supplemental Application (Astellas Pharma US, Inc.)

  The FDA approved a supplemental application for IZERVAY (avacincaptad pegol) from Astellas Pharma US, expanding its label for geographic atr…

• FDA approval · 2025-02-12
  FDA Approved: IZERVAY — Supplemental Application (Astellas Pharma US, Inc.)

  The FDA approved a supplemental application for IZERVAY (avacincaptad pegol) submitted by Astellas Pharma US, Inc.

• FDA approval · 2024-12-20
  FDA Approved: SYFOVRE — Supplemental Application (Apellis Pharmaceuticals, Inc.)

  The FDA approved a supplemental application for SYFOVRE (pegcetacoplan) from Apellis Pharmaceuticals.

• FDA approval · 2023-02-17
  FDA Approved: SYFOVRE — Original Application (Apellis Pharmaceuticals, Inc.)

  FDA approved SYFOVRE (pegcetacoplan) from Apellis Pharmaceuticals for geographic atrophy associated with age-related macular degeneration, m…